Lipid A and liposomes containing lipid A as antigens and adjuvants

被引:35
作者
Alving, Carl R. [1 ]
Rao, Mangala [1 ]
机构
[1] Walter Reed Army Inst Res, US Mil HIV Vaccine Res Program, Div Retrovirol, Dept Adjuvant & Antigen Res, Rockville, MD 20350 USA
关键词
lipopolysaccharide; endotoxin; lipid A; liposomes; antibodies to lipids; adjuvants; innate immunity; adaptive immunity; natural antibodies; polyreactive antibodies; HIV-1; neutralizing antibodies;
D O I
10.1016/j.vaccine.2007.12.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lipid A derived from Gram-negative bacterial. lipopolysaccharide is a potent adjuvant and antigen. Incorporation of lipid A into liposomes renders the liposomes themselves immunogenic, resulting in generation of specific antibodies that recognize either the individual liposomal lipids, or the unique pattern presented by the combination of lipids. Using liposomes containing lipid A, numerous polyclonal antisera and monoclonal antibodies have been produced against phospholipids, cholesterol, glycosphingolipids, and lipid A. Many of these antibodies have binding characteristics that are apparently similar to natural antibodies that are normally present in all human sera, and also antibodies that arise in response to various infections. Such antibodies probably represent a bridge between innate and adaptive immunity. The possibile utility of liposomes containing lipid A as a constituent of certain types of novel vaccines was suggested by the observation that murine monoclonal antibodies to liposomal. phosphatidytinositol-4-phosphate neutralized primary isotates of two different clades of HIV-1 in a human peripheral. blood mononuctear cell. neutralization assay. Published by Elsevier Ltd.
引用
收藏
页码:3036 / 3045
页数:10
相关论文
共 101 条
[1]   Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Milman, J ;
Mandomando, I ;
Spiessens, B ;
Guinovart, C ;
Espasa, M ;
Bassat, Q ;
Aide, P ;
Ofori-Anyinam, O ;
Navia, MM ;
Corachan, S ;
Ceuppens, M ;
Dubois, MC ;
Demoitié, MA ;
Dubovsky, F ;
Menéndez, C ;
Tornieporth, N ;
Ballou, WR ;
Thompson, R ;
Cohen, J .
LANCET, 2004, 364 (9443) :1411-1420
[2]  
ALVING BM, 1987, CLIN EXP IMMUNOL, V69, P403
[3]   4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues [J].
Alving, Carl R. .
AIDS, 2008, 22 (05) :649-651
[4]   HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies (Review) [J].
Alving, Carl R. ;
Beck, Zoltan ;
Karasavva, Nicos ;
Matyas, Gary R. ;
Rao, Mangala .
MOLECULAR MEMBRANE BIOLOGY, 2006, 23 (06) :453-U1
[5]   Antibodies to lipids and liposomes: Immunology and safety [J].
Alving, Carl R. .
JOURNAL OF LIPOSOME RESEARCH, 2006, 16 (03) :157-166
[6]   ANTIBODIES TO LIPOSOMES, PHOSPHOLIPIDS AND PHOSPHATE-ESTERS [J].
ALVING, CR .
CHEMISTRY AND PHYSICS OF LIPIDS, 1986, 40 (2-4) :303-314
[7]   Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism [J].
Alving, CR ;
Wassef, NM .
IMMUNOLOGY TODAY, 1999, 20 (08) :362-366
[8]  
ALVING CR, 1991, CRIT REV IMMUNOL, V10, P441
[9]   LIPOPOLYSACCHARIDE, LIPID-A, AND LIPOSOMES CONTAINING LIPID-A AS IMMUNOLOGICAL ADJUVANTS [J].
ALVING, CR .
IMMUNOBIOLOGY, 1993, 187 (3-5) :430-446
[10]  
ALVING CR, 1999, Patent No. 5888519